Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to demonstrate the long-term safety of vildagliptin in patients with
type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin,
thiazolidinedione, α-glucosidase inhibitor (α-GI), rapid-acting insulin secretagogues in the
treatment of type 2 diabetes in Japan.